LFG
CPRX

Larson Financial Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Larson Financial Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.1K Buy
1,861
+14
+0.8% +$334 ﹤0.01% 1403
2025
Q4 		$43.1K Buy
1,847
+1,564
+553% +$34.8K ﹤0.01% 1305
2025
Q3 		$5.58K Buy
283
+158
+126% +$3.25K ﹤0.01% 2317
2025
Q2 		$2.71K Buy
125
+114
+1,036% +$2.69K ﹤0.01% 2308
2025
Q1 		$267 Sell
11
-2,340
-100% -$52.7K ﹤0.01% 2728
2024
Q4 		$49.1K Sell
2,351
-654
-22% -$14.1K ﹤0.01% 909
2024
Q3 		$59.7K Buy
3,005
+2,994
+27,218% +$55.5K ﹤0.01% 854
2024
Q2 		$170 Buy
+11
New +$171 ﹤0.01% 2115
2023
Q2 		– Sell
-1
Closed -$17 – 1579
2023
Q1 		$17 Hold
1
– – ﹤0.01% 1530
2022
Q4 		$19 Buy
+1
New +$15 ﹤0.01% 1488

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Larson Financial Group's CPRX Position: Q1 2026 in Review

Larson Financial Group increased its Catalyst Pharmaceutical (CPRX) stake by 0.76% in Q1 2026, buying an estimated $334 and bringing the position to 1,861 shares worth $46.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1403.

Larson Financial Group first reported a position in CPRX in Q4 2022 and has held it in 10 quarters since. The position peaked at $59.7K in Q3 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Larson Financial Group held 1,861 shares of Catalyst Pharmaceutical worth $46.1K as of Q1 2026.
  • Larson Financial Group bought 14 Catalyst Pharmaceutical shares in Q1 2026, an estimated $334.
  • Catalyst Pharmaceutical made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #1403 holding.
  • Larson Financial Group first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 10 quarters since.
  • Larson Financial Group's Catalyst Pharmaceutical position peaked at $59.7K in Q3 2024.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.